Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019–2020
Thomas Williams,Sandra Jackson,Ian Barr,Shabana Bi,Jinal Bhiman,Joanna Ellis,Anne von Gottberg,Stephen Lindstrom,Teresa Peret,Sanjiv Rughooputh,Mariana Viegas,Siddhivinayak Hirve,Maria Zambon,Wenqing Zhang,WHO RSV Surveillance Group,Ndongo Dia,Norosoa Razanazatovo,Ajaeb Dakhilalla M. H. Al‐Nabet,Abdinasir Abubakar,Almiro Tivane,Amal Barakat,Amel Naguib,Ammar Aziz,Andrea Vicari,Ann Moen,Arunkumar Govindakarnavar,Aron Hall,Badarch Darmaa,Bastien Nathalie,Belinda Herring,Braulia C. Caetano,Brett Whittaker,Elsa Baumeister,Emmanuel Nakouné,Erica Guthrie,Francis Inbanathan,Harish Nair,Harry Campbell,Herve A. Kadjo,Hicham Oumzil,Jean‐Michel Heraud,Joshua A. Mott,Joyce Namulondo,Juliana Leite,Karen Nahapetyan,Lubna Al Ariqi,Mahmoud Hamad Ibraheem Gazo,Mandeep Chadha,Maria Pisareva,Marietjie Venter,Marilda M. Siqueira,Mayan Lumandas,Mbayame Niang,Mona Albuaini,Muhammad Salman,Steve Oberste,Padmini Srikantiah,Patrick Tang,Paula Couto,Peter Smith,Peter Valentine Coyle,Philippe Dussart,Phuong Nam Nguyen,Pilailuk Akkapaiboon Okada,Pushpa Ranjan Wijesinghe,Reuben Samuel,Richard Brown,Richard Pebody,Rodrigo Fasce,Runa Jha,Stephen Lindstrom,Sue Gerber,Varsha Potdar,Xiaomin Dong,Yi Mo Deng
DOI: https://doi.org/10.1111/irv.13073
2023-01-20
Influenza and Other Respiratory Viruses
Abstract:Background External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019–2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV‐A and RSV‐B. This manuscript describes the preparation, distribution, and analysis of the 2019–2020 WHO RSV EQA. Methods Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in‐house or commercial assays already in use at their laboratories. Results An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping. Conclusions The WHO RSV EQA 2019–2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
infectious diseases,virology